(Yicai Global) Nov.29 -- Maccura Biotechnology will expand to the US market to upgrade the branding of its diagnostic tests. 

Maccura's board meeting approved the plan to set up a unit in Delaware, the Chengdu-based company said in a statement yesterday. 

Maccura aims to build foreign sales channels, seek new partners and methods for in vitro diagnostics, which will help it to develop international standards, the statement added. 

Founded in 1994, Maccura makes and sells reagents in China and abroad. Its operating income rose 44 percent to CNY2 billion (USD287.9 million) from January to September. The net profit attributable to shareholders increased 19 percent to CNY355 million (USD51.1 million). 

Editor: Emmi Laine